Last reviewed · How we verify

NCT06710873

Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

Active, enrolled Last updated 25 March 2025
What this trial tests

trial testing TYRX Absorbable Antibacterial Envelope in CIED Infection in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 December 2023
Primary endpoint
9 October 2024
1 March 2026

Quick facts

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment50
Start date1 December 2023
Primary completion9 October 2024
Estimated completion1 March 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

18 and older, any sex, with CIED Infection or TYRX Absorbable Antibacterial Envelope. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing